LCA3 AAV siRNA Pooled Vector

Cat. No.
1.0 μg

Lead Time
3 to 4 weeks
Cat. No. 61125161
Name LCA3 AAV siRNA Pooled Vector
Unit 1.0 μg
Gene Name LCA3
Species Human
Vector Map pAAV-siRNA-GFP-hGH-amp (click blue link to view)
System AAV Vector
Target Sequence Sequence available upon placing order
Vector Size 6013
QC Restriction enzyme digest and sequencing.
Disclaimer 1. Disclaimer for accession number: The provided accession number refers to the transcript (mRNA) sequence the siRNA product targets. Please verify that this is the desired transcript sequence by cross-referencing. This is important because a single gene can have multiple different transcripts owing to naturally occurring variations. All sales are final. 2. Disclaimer for intended use: All of abm's vectors and viral particles are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its vector(s) in therapeutic/diagnostic application(s). 3. Disclaimer for extra nucleotides: Cloning may lead to the insertion of extra nucleotides at the 5' or 3' end of the target sequence which, in most cases, is innocuous to the stability/functionality of the construct.
Guarantee Our RNA interference AAV vectors contain siRNAs. We employ a dual convergent promoter system where the sense and antisense strands of the siRNA are expressed by two different promoters rather than in a hairpin loop - to avoid any possible recombination events that can occur. ABM is confident that our pooled siRNA AAV vectors, when packaged into virus, will result in over 70% knockdown of gene expression within selected target cells showing 100% GFP expression. If this is not the case, we will provide a one-time, free replacement for a new pooled siRNA AAV vector expressing alternative siRNA sequences. To qualify for this replacement, the viruses must be used at a MOI >5,000 and the target cells selected and assayed 5-7 days post-infection. Customers must provide adequate data such as qPCR (using appropriate controls) to evaluate the level of gene expression. The replacement pooled siRNA AAV vector will not be covered by the same guarantee, and if this replacement is also considered to be ineffective then it is most likely the gene is not susceptible to siRNA knockdown. ABM limits its obligation and liability to providing one replacement of the pooled siRNA AAV vector product only, subject to a replacement fee. Before sending your inquiry, please make sure you have optimized your experiments as far as possible, this includes (where applicable) increasing your MOI and the duration of infection and carrying out clone screening before assaying for knockdown. Please send all replacement inquiries and experimental data to [email protected]
Caution This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information.
Material Citation If use of this material results in a scientific publication, please cite the material in the following manner: Applied Biological Materials Inc, Cat. No. 61125161
Print & Download Datasheet
  • Liang, Y., Song, X., Li, Y., Su, P., Han, D., Ma, T., … Yang, Q. "circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer" Oncogene 38(42):6850–6866 (2019). DOI: 10.1038/s41388-019-0926-z.
  • Verma, M., Asakura, Y., & Asakura, A. "Inhibition of microRNA‐92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy–related phenotype in mdx mice" Muscle & Nerve 59(5):594–602 (2019). DOI: 10.1002/mus.26433.
  • Wu., Chien-Wei., . "Downregulation of MiR-144 by Triptolide Enhanced p85α−PTEN Complex Formation Causing S Phase Arrest of Human Nasopharyngeal Carcinoma Cells" European Journal of Pharmacology 855:137-148 (2019). DOI: 10.1016/j.ejphar.2019.04.052..
  • Wu, M.-J., Chen, Y.-S., Kim, M. R., Chang, C.-C., Gampala, S., Zhang, Y., … Chang, C.-J. "Epithelial-Mesenchymal Transition Directs Stem Cell Polarity via Regulation of Mitofusin" Cell Metabolism 29(4):993–1002.e6 (2019). DOI: 10.1016/j.cmet.2018.11.004.
  • Xiang, X., Zhou, Y., Sun, H., Tan, S., Lu, Z., Huang, L., & Wang, W. "Ivabradine abrogates TNF-α-induced degradation of articular cartilage matrix" International Immunopharmacology 66:347–353 (2019). DOI: 10.1016/j.intimp.2018.11.035.
  • Zhou, Y., Lei, J., Xie, Q., Wu, L., Jin, S., Guo, B., ... & Zhang, J. "Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5" Science Advances 5(11):eaax0629 (2019).
  • Zhu, R., Xue, X., Shen, M., Tsai, Y., Keng, P. C., Chen, Y., … Chen, Y. "NFκB and TNFα as individual key molecules associated with the cisplatin-resistance and radioresistance of lung cancer" Experimental Cell Research 374(1):181–188 (2019). DOI: 10.1016/j.yexcr.2018.11.022.
This product has no review yet.
Other LCA3 Products
LCA3 Human

LCA3 Lentiviral Vector
LCA3 AAV Vector
LCA3 Adenovirus Vector
LCA3 Protein Vector
LCA3 ORF Vector
LCA3 siRNA Vector
LCA3 miRNA Vector
LCA3 3'UTR Vector
LCA3 CRISPR Knockout Vector
LCA3 CRISPR Activation Vector
LCA3 Control Vectors & Viruses Vector
LCA3 circRNA Vector
LCA3 Internal Vector